item management s discussion and analysis of financial condition and results of operations results of operations fiscal compared to fiscal revenue for fiscal was  an increase of from revenue of  in fiscal this increase is primarily the result of an increase in unit volume as the result of the introduction of two new dermatology products 
international revenue as a percentage of total revenue represented of revenue in  compared to in fiscal gross margin increased to in fiscal from in fiscal  reflecting volume increases in the company s dermatology products 
research and development spending decreased to  in fiscal from  in fiscal as a percent of revenue  research and development spending decreased to in fiscal from in fiscal the company continues to build on its strengths in the urology and dermatology markets and internal development efforts have been refocused accordingly 
the company expects expenditures for research and development to be between and of revenue going forward 
selling  general and administrative expenses decreased to  in fiscal from  in fiscal as a result of both reduced spending and higher revenue  selling  general and administrative spending as a percentage of revenue  decreased to in fiscal from in fiscal interest income increased to  in fiscal from  in fiscal as a result of increased average cash balances 
other expense in fiscal of  and other income in fiscal of  results primarily from foreign currency transactions 
the company s consolidated net income includes a net loss of  from the first year of operation of its new wholly owned subsidiary  candela skin care centers  inc cscc 
while sites open for a year or more are expected to be profitable  those open a year or less are expected to unfavorably impact operating results until reaching maturity 
provision for income taxes in fiscal results primarily from taxable income in the company s subsidiary in japan and alternative minimum tax in the us income taxes provided for in fiscal reflect an effective tax rate of 
this is lower than the us statutory rate of  because of the utilization of a deferred tax asset that will be recognized when filing the us taxes 
this tax rate includes both foreign taxes  which generally are higher than the us statutory rate  state income taxes  and the effect of utilizing the deferred tax asset 
as a result of the foregoing factors  the company realized a net income of  or per share in fiscal  compared to a net loss of  or in fiscal fiscal compared to fiscal revenue for fiscal was  a decrease of from revenue of  in fiscal this decrease is primarily the result of a change in product mix toward lower priced products offset in part by an increase in unit volume 
international revenue as a percentage of total revenue represented of total revenues in fiscal down from in fiscal gross margin decreased to in fiscal from in fiscal  reflecting the change in product mix toward lower priced products as well as volume decreases in the company s higher margin urology products 
research and development spending decreased to  in fiscal from  in fiscal as a percent of revenue  research and development spending was in both fiscal and fiscal the company continues to build on its strengths in the urology and dermatology markets and internal development efforts have been refocused accordingly 
the company expects expenditures for research and development to be between and of revenue going forward 
selling  general and administrative expenses increased to  in fiscal from  in fiscal this increase is primarily attributable to increases in labor and related expenses as a result of an increase in the company s direct salesforce 
as a result of both increased spending and lower revenue  selling  general and administrative spending as a percentage of revenue  increased to in fiscal from in fiscal interest income decreased to  in fiscal from  in fiscal as a result of lower average cash balances 
other income in fiscal and results primarily from foreign currency transactions as well as losses relating to the disposal of property and equipment 
provision for income taxes in fiscal results from taxable income in the company s subsidiary in japan 
income taxes provided for in fiscal reflect an effective tax rate of 
this is higher than the us statutory rate of  because it includes both foreign taxes  which generally are higher than the us statutory rate  and state income taxes 
as a result of the foregoing factors  the company incurred a net loss of  or per share in fiscal  compared to net income of  or per share in fiscal liquidity and capital resources cash and equivalents at june  increased to  from  at july  this increase results primarily from net income of  and by negotiating more favorable terms for accounts payable 
these sources were offset in part by a  increase in trade receivables 
during the fiscal year  the company utilized  in cash in the operations of its wholly owned subsidiary  candela skin care centers  inc  cscc 
the company expects that cscc will continue to require cash during its infancy and development stages 
during fiscal  the company borrowed  on a two year note with a foreign bank 
the current value of this liability is  as converted at the current exchange rates 
during fiscal  the company borrowed  on a two year note with a foreign bank 
the company s remaining short term and long term debt is comprised solely of capital lease obligations  which was  and  at june   versus  and  at july  the company believes its existing funds are sufficient to meet the operating requirements of the company for the foreseeable future 
cautionary statements in addition to the other information in this annual report on form k  the following cautionary statements should be considered carefully in evaluating the company and its business 
statements contained in this form k that are not historical facts including without limitation  statements concerning anticipated operational and capital expense levels and such expense levels relative to the company s total revenues and other information provided by the company and its employees from time to time may contain certain forward looking information  as that term is defined by i the private securities litigation reform act of the act and ii in releases made by the securities and exchange commission the sec 
the factors identified in the cautionary statements below  among other factors  could cause actual results to differ materially from those suggested in such forward looking statements 
the cautionary statements below are being made pursuant to the provisions of the act and with the intention of obtaining the benefits of the safe harbor provisions of the act 
variability of quarterly operating results 
the company s quarterly operating results may vary significantly from quarter to quarter  depending upon factors such as the timing of product sales  the timing of expenditures in anticipation of future product orders  the introduction and market acceptance of new products  effectiveness in managing manufacturing processes  changes in cost and availability of labor and product components  order cancellations  the budgetary cycles of its customers  and the timing of regulatory approvals 
the company s ability to accurately forecast future revenues and income for any period is necessarily limited  and any forward looking information provided from time to time by the company represents only management s then best current estimate of future results or trends  and actual results may differ materially from those contained in the company s estimates 
potential volatility of stock price 
there has been significant volatility in the market price of securities of companies in the medical device industry 
factors such as announcements of new products by the company or its competitors  quarterly fluctuations in the financial results of the company or its competitors  shortfalls in the company s actual financial results compared to results previously forecasted by stock market analysts  conditions in the medical device industry and the financial markets and the economy generally could cause the market price of the company s securities to fluctuate substantially and may adversely affect the price of the company s securities 
risks associated with international operations 
a significant portion of the company s revenues are attributable to international operations and revenues from international operations are likely to continue to be significant in future periods 
the company s international business and financial performance may be adversely affected by a number of factors  including without limitations to fluctuations in exchange rates  tariffs and other trade barriers  adverse tax regulation  and adverse political and economic conditions 
adverse effect on the company s international operations may have materially adverse effects on the company s overall financial condition and operating results 
governmental regulation 
medical devices are subject to united states food and drug administration fda approval before they can be utilized for clinical studies or sold commercially 
in addition  the company s activities in connection with its cscc business may subject the company to additional regulation under state and federal laws 
the process for obtaining the necessary approvals and compliance with applicable regulations can be costly and time consuming 
many foreign countries in which the company markets or may market its products have similar regulatory bodies and restrictions 
there is no assurance the company will be able to obtain any such government approvals or successfully comply with any such regulations in a timely and cost effective manner  if at all  and failure to do so may have an adverse effect on the company s financial condition and results of operations 
risks associated with product liability 
the administration of medical and cosmetic treatments using laser products is subject to various risks of physical injury to the patient which may result in product liability or other claims against the company 
the costs and resources involved in defending or settling any such claims  or the payment of any award in connection therewith  may adversely affect the company s financial condition and operating results 
the company maintains product liability insurance  but there is no assurance that its policy will provide sufficient coverage for any claim or claims that may arise  or that the company will be able to maintain such insurance coverage on favorable economic terms 
rapid technological change  competition 
the medical laser industry is subject to rapid and substantial technological development and product innovations 
the company  to be successful  must be responsive to new developments in laser technology and applications of existing technology  and the company s financial condition and operating results may be adversely affected by the failure of new or existing products to compete favorably in response to such technological developments 
in addition  the company competes against numerous other companies offering products similar to the company s and or alternative products and technologies  some of which have greater financial  marketing and technical resources than the company 
there can be no assurance the company will be able to compete successfully 
reliance on attracting and retaining key employees 
the company s success will depend in large part on its ability to attract and retain highly qualified scientific  technical  managerial  sales and marketing  management and other personnel 
competition for such personnel is intense and any decline in the company s ability to attract and retain such personnel may have adverse effects on its financial condition and operating results 

